8/6/2014 11:06:24 AM
DUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK) today announced that on July 29, 2014 the U.S. Patent and Trademark Office granted the company a new patent related to MNK-155. The patent, U.S. Patent Number 8,790,694 contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of MNK-155 and conveys the same period of exclusivity as did the patent granted in 2013 for the company’s product XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII).
MNK-155 is Mallinckrodt’s investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. The release profile of MNK-155 combines Mallinckrodt-proprietary technology and Depomed’s advanced Acuform® drug delivery technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by